Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis

PS-106-An international, randomized, placebo-controlled phase 2 trial demonstrates novel effects of DGAT2 antisense inhibition in reducing steatosis without causing hypertriglyceridemia in T2DM patients

(2019) Rohit Loomba et al.   JOURNAL OF HEPATOLOGY

DGAT2 Inhibition Alters Aspects of Triglyceride Metabolism in Rodents but Not in Non-human Primates

(2018) David G. McLaren et al.   Cell Metabolism

An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans

(2018) Adil Mardinoglu et al.   Cell Metabolism

Mechanistic Characterization of Long Residence Time Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)

(2018) Brandon Pabst et al.   BIOCHEMISTRY

Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib

(2018) Saumya Jayakumar et al.   JOURNAL OF HEPATOLOGY

Exome chip meta-analysis identifies novel loci and East Asian–specific coding variants that contribute to lipid levels and coronary artery disease

(2017) Xiangfeng Lu et al.   NATURE GENETICS

Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis

(2017) Anna M. Diehl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

(2017) A. Michael Lincoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Roles of Acyl-CoA:Diacylglycerol Acyltransferases 1 and 2 in Triacylglycerol Synthesis and Secretion in Primary Hepatocytes

(2015) C. Li et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop

(2015) Arun J. Sanyal et al.   HEPATOLOGY

The Diacylglycerol Acyltransferase 1 Inhibitor, Pradigastat, Was Well Tolerated in a 52-Week Clinical Trial in FCS Patients

(2015) Erik S.G. Stroes et al.   Journal of Clinical Lipidology

Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2)

(2015) Kentaro Futatsugi et al.   JOURNAL OF MEDICINAL CHEMISTRY

NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels

(2014) K. E. Corey et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

World Gastroenterology Organisation Global Guidelines

(2014) Douglas R. LaBrecque et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Intestine-Targeted DGAT1 Inhibition Improves Obesity and Insulin Resistance without Skin Aberrations in Mice

(2014) Naoto Tsuda et al.   PLoS One

Non-alcoholic fatty liver disease

(2014) N. Sattar et al.   BMJ-British Medical Journal

Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia

(2013) Victor A. Zammit   BIOCHEMICAL JOURNAL

Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial

(2013) H. Denison et al.   DIABETES OBESITY & METABOLISM

The DGAT1 inhibitor Pradigastat Decreases Chylomicron Secretion and Prevents Postprandial Triglyceride Elevation in Humans

(2013) Charles Daniel Meyers et al.   Journal of Clinical Lipidology

A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma

(2013) Masato Fujii et al.   Medical Molecular Morphology

Smooth Muscle α Actin (Acta2) and Myofibroblast Function during Hepatic Wound Healing

(2013) Don C. Rockey et al.   PLoS One

Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD

(2012) Z. Permutt et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging

(2012) Arian Mashhood et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Targeting Acyl-CoA:Diacylglycerol Acyltransferase 1 (DGAT1) with Small Molecule Inhibitors for the Treatment of Metabolic Diseases

(2011) Jingsong Cao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites

(2010) Brent A. Neuschwander-Tetri   HEPATOLOGY

Histopathology of nonalcoholic fatty liver disease

(2010) Elizabeth M Brunt   WORLD JOURNAL OF GASTROENTEROLOGY

Obesity-Associated Liver Disease

(2008) Giulio Marchesini et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Thematic Review Series: Glycerolipids.DGAT enzymes and triacylglycerol biosynthesis

(2008) Chi-Liang Eric Yen et al.   JOURNAL OF LIPID RESEARCH

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

(2008) Stefano Romeo et al.   NATURE GENETICS